Sanofi inaugerate new vaccine facility in Val de Reuil
Sanofi Pasteur, the vaccines division of French drug major Sanofi-Aventis, has inaugerated a new vaccine production facility in Val de Reuil in the North of France. The highly-automated facility can produce vaccines against 20 diseases and is designed to be ready to switch to manufacture flu vaccines, in the event of an epidemic. The plant cost 100.0 million euros ($154.8 million) and is part of a 200.0-million euro investment project in the Val de Reuil area. Sanofi has invested over 1.0 billion euros on industrial capacities over the last five years.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze